Replies to post #138150 on Biotech Values

[DewDiligence]

Re: ABT-Galapagos JAK collaboration

Isn't ABT the partner one would want given their colossal success with Humira in the RA space? Really do think Galapagos has the right partner here. They just need to deliver on the data.

One fly in the ointment: ABT has its own in-house JAK inhibitor. Inasmuch as ABT has only taken an option (albeit an expensive one) on GLPG0634, ABT could yet end up backing its own JAK compound rather than the one from Galapagos.